trial

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

NCTId NCT03793712
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 168 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2020-08-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
168 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-12-27
Primary completion
2020-08-20
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Lu AF11167 (1-2 mg/day)Lu AF11167 (3-4 mg/day)

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

53 total
Burgas, BulgariaKazanlak, BulgariaLovech, BulgariaNovi Iskar, BulgariaPleven, BulgariaPlovdiv, BulgariaSevlievo, BulgariaSofia, BulgariaVarna, BulgariaVarna, BulgariaVarna, BulgariaVeliko Tarnovo, Bulgaria

Linked catalysts

1
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Sc — primary completion2020-08-20

Facts & assertions

4 sourced
Enrollment
168
Phase
PHASE2
Primary Completion Date
2020-08-20
Status
TERMINATED
relationships
The graph out of here
drug
Lu AF11167 (1-2 mg/day)
drug
Lu AF11167 (3-4 mg/day)
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication